Esophageal Temperature Management in Patients Suffering from Traumatic Brain Injury

Faraaz Bhatti, MD, MRCEM,1 Melissa Naiman, PhD,2 Alexander Tsarev, MD,3 and Erik Kulstad, MD, MS4

Traumatic brain injury (TBI) is a leading cause of death in the United States, and represents 2.5 million Emergency Department attendances, admissions into hospital, and deaths. A range of temperature modulating devices have been used to proactively cool TBI patients; however, there are currently no uniform targeted temperature management (TTM) guidelines in this patient population. Esophageal temperature management (ETM) is a relatively new TTM modality and the purpose of this study is to determine whether ETM is effective in controlling core temperature in TBI cases. This prospective interventional trial was a single-site study that enrolled 12 patients who received a TTM protocol using ETM. Eleven out of 12 patients reached target temperature during the first 10 hours of treatment. A total of 480 temperature measurements were recorded; 85% of the total measurements were within ±1°C of target temperature (408 measurements) and 75% were within ±0.5°C of target temperature (360 measurements). The average time to target was 5.83±5.01 hours (range 1–20), with an average cooling rate of 0.58°C/h (range 0.15–1.5°C/h). This prospective interventional trial supports that ETM is a feasible TTM modality for severe TBI cases. The esophageal heat transfer device used in this study demonstrated comparable or superior performance to other commercially available TTM modalities, and the low adverse event rate may offer advantages over more invasive methods with reported higher complication rates.

Keywords: temperature mechanisms, traumatic brain injury, brain trauma, cooling strategies, hyperthermia, targeted temperature management, esophageal temperature, heat transfer device

Introduction

Traumatic brain injury (TBI) is a leading cause of death in the United States, and represents 2.5 million Emergency Department attendances, admissions into hospital, and deaths (CDC, 2015; Faul and Coronado, 2015). Primary TBI leads to secondary injury over a period of time—and this can lead to blood–brain barrier dysregulation and worsening patient outcomes (Kinoshita, 2016). TBIs can be further be subdivided into minor (75%), moderate (15%), and severe (10%). Patients who survive severe brain injury are often left with life-changing neuropsychological disabilities—which approximately 90,000 people in the United States experience.

A key aim of treating this complex cohort of patients is to prevent secondary brain injury (Marion and Regasa, 2014). Pyrexia, typically defined as core body temperature of ≥38.3°C, is associated with adverse outcomes on both morbidity and mortality in TBI cases and targeted temperature management (TTM) is often used to prevent further brain insult when acetaminophen or NSAIDs fail (Polderman, 2008; Crossley et al., 2014; Marion and Regasa, 2014). Potential protective mechanisms include suppressing destructive mechanisms, including excitotoxicity, neuroinflammation, spreading depolarizations, and many others (Greer et al., 2008; Badjatia, 2009; Puccio et al., 2009).

A range of temperature modulating devices, including cooling blankets, gel pads, and intravascular catheters, have
been used to proactively cool TBI patients; however, there have been no uniform TTM guidelines in this patient population (Abou El Fadl and O’Phelan, 2017).

Esophageal temperature management (ETM) is a relatively new TTM modality, which has demonstrated effectiveness in postcardiac arrest (Markota et al., 2016; Goury et al., 2017; Hegazy et al., 2017), non-TBI (Khan et al., 2018), burn (Williams et al., 2016), and refractive pyrexia cases with infectious origins (Hegazy et al., 2015; Markota et al., 2017). The purpose of this study is to determine whether ETM is effective in controlling core temperature in TBI cases.

Materials and Methods

Study design

This prospective interventional trial was a single-site study approved by the Dnipropetrovsk State Medical Academy Ethics Committee (ClinicalTrials.gov Identifier: NCT02420639). Written informed consent was obtained from each patient’s next of kin or legal representative. All subjects were at least 18 years of age and diagnosed with severe TBI, for which the treating physician ordered TTM. Temperature management method was selected by physician discretion.

Patients with known esophageal deformity, evidence of esophageal trauma, known ingestion of acidic or caustic poisons within the prior 24 hours, body mass less than 40 kg, known pregnancy, terminal disease or “do not resuscitate order,” unstable hemodynamic conditions, or preexisting severe cardiac conductive disorder requiring pacing were excluded. Patients were followed up to ICU discharge or to 30 days after enrollment.

All participants received TTM performed with an esophageal heat transfer device (EnsoETM ECD02B; Attune Medical, Chicago, IL) in accordance with its Instructions for Use (at the time of the study, the ECD02B was labeled for a 36 hour duration of use. In 2016, the ECD02 was cleared for 120 hour duration of use). In brief, the esophageal heat transfer device is a disposable, triple-lumen system that replaces a traditional orogastric tube in the esophagus (Fig. 1). Two lumens are attached to an external heat exchange unit (Blanketrol II; Cincinnati SubZero, Cincinnati, OH) and the third, independent, lumen allows gastric access. Temperature-controlled water circulates within the device to affect heat transfer; proximity to the heart and great vessels facilitates core warming or cooling.

Target temperature for the TTM protocol was assigned by provider discretion; heat exchange unit set point and water temperature were recorded hourly. Patient core temperature was measured hourly by Foley thermistor and confirmed by rectal temperature sensor readings. Adverse events specifically monitored included the following: cardiac arrhythmias, severe bradycardia, myocardial infarction/reinfarction, dysphagia, odynophagia, aspiration pneumonia, nonaspiration pneumonia, reflux, esophageal injury, and esophagitis.

Results

A cohort of 12 severe TBI patients were enrolled between August 2015 and May 2016. Mean age was 42 ± 16 years, and 11 were male. Patient age, gender, weight, BMI, and initial GCS score are shown in Table 1. Specific diagnoses included subdural hematoma (five patients), hemorrhagic contusion (three patients), subarachnoid hemorrhage (two patients),
intracranial hematoma (one patient), and epidural hematoma (one patient). Six patients underwent craniectomy.

Most patients (10) were assigned a target temperature of 34.5°C, one patient was assigned a target of 35°C, and one patient was initially assigned a target of 34.8°C, which was adjusted to 34°C during the third hour and maintained for the remaining 36 hours of treatment. Figure 2 shows the TTM protocol target temperature and the temperature profile for each individual patient. Most patients received propofol and fentanyl for sedation, and six patients also received the nondepolarizing neuromuscular blocking agent pipecuronium.

Eleven out of 12 patients reached target temperature during the first 10 hours of treatment. A total of 480 temperature measurements were recorded; 85% of the total measurements were within ±1°C of target temperature (408 measurements), and 75% were within ±0.5°C of target temperature (360 measurements). The average time to target was 5.83 ± 5.01 hours (range 1–20), with an average cooling rate of 0.58°C/h (range 0.15–1.5°C/h).

Survival outcomes were not among the analysis endpoints, condition at discharge was recorded. All patients survived to discharge, with CPC scores of 1 (three patients), 2 (five patients), 3 (three patients), and 4 (one patient). One adverse event, a small volume left hydrothorax, was reported, but did not require treatment and was ultimately determined to be unrelated to the study device.

Discussion

Although this study was not designed to make a direct comparison between ETM and other TTM modalities, its effectiveness is comparable or superior to other modalities used during TBI treatment reported in the literature. In one of the earliest studies of hypothermia for TBI, Marion et al. (1997) used cooling blankets and nasogastric lavage to attain goal temperature in a mean of 10 hours after injury. Clifton et al. (2001) used ice packs, gastric lavage with iced fluids, and temperature-control pads to achieve target temperature in 8.4 ± 3.0 hours. A study of induced normothermia in TBI patients using a triple-lumen intravascular cooling catheter attained target temperature in approximately 6 hours (interpolating from temperature graph) (Puccio et al., 2009).

The National Acute Brain Injury Study: Hypothermia II compared normothermia (37°C) with two hypothermia protocols (33°C and 35°C). Patients randomized to the hypothermia group were initially cooled to 35°C with up to 2 L of cold crystalloid and application of wet sheets or gel packs and then further cooled to 33°C using chilled intravenous crystalloids, gastric lavage with cold water, and an advanced hydrogel pad system. The mean time to target was 2.6 ± 1.2
hours for patients assigned to the 35°C protocol and 4.4 ± 1.5 hours for patients assigned to the 33°C protocol (Clifton et al., 2011). In the Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury—Randomized Clinical Trial (POLAR-RCT), hypothermia was induced by patient exposure, a bolus of up to 2 L intravenous ice-cold (4°C) 0.9% saline, and surface-cooling wraps to reach an initial temperature of 35°C.

Patients who were not at risk for severe bleeding were further cooled to 33°C±0.5°C with surface wraps. Among the 233 (89.6%) patients in the hypothermia group who reached target temperatures, median time from injury to the initial 35°C target was 2.5 hours (IQR, 0.8–5.5). Among the 186 patients (71.5%) who were assigned to the 33°C target, median time from injury to target was 10.1 hours (IQR, 6.8–15.9). Study-wide, the average time from injury to randomization was 1.9 hours (IQR, 1.0–2.7).

However, a substantial subset of patients assigned to the hypothermia group did not receive the intended treatment; 85 evaluable patients (33%) in the hypothermia group received less than 48 hours of hypothermia (33°C–35°C), and 27% of patients in the hypothermia group never reached the final target temperature of 33°C (Cooper et al., 2018). Another aspect of device performance to consider when evaluating ETM is adverse event rates. The study protocol included active adverse event monitoring. Only one patient experienced a reportable event, a hydrothorax that did not require treatment and which was not felt to be device related.

In comparison, more invasive methods report higher complication rates, including occult or asymptomatic thrombosis, some of which are considered higher risk due to their more proximal (including caval) location (Simosa et al., 2007; Prunet et al., 2009; Lau et al., 2010; Gierman et al., 2013; Maze et al., 2014; Gillon et al., 2015; Reccius et al., 2015; Wang et al., 2018). The thrombosis risk from endovascular cooling catheters has been suggested to be higher than standard central line intravascular catheters due to differences in materials (Wang et al., 2018), or shape, where the nonuniform diameter may cause distal eddy flow, blood pooling, and stagnation, in turn, promoting activation of coagulation and the formation of clot in a more proximal location than can be easily visualized with standard compression ultrasonography (Gierman et al., 2013; Gillon et al., 2015; Reccius et al., 2015).

One major limitation of this study is the small sample size. As is often the case in small interventional trials, the summary statistics reported in this study were heavily influenced by a single patient (Patient 2). Removing this patient from analysis could not be statistically justified, but the clinical details are noteworthy.

In addition to severe TBI, Patient 2 had significantly delayed care; over 20 minutes elapsed between the witnessed injury and ambulance arrival and almost 4 hours elapsed before advanced life support and admission to the study site while comatose. This patient’s first recorded temperature, 37.5°C, was already warmer than typical in this cohort and he remained approximately 2°C above target for the first 19 hours of treatment, at which point the treating clinician elected to adjust the target temperature from 34.5°C to 36.6°C.

Cooling rates are known to be slower in patients with central fever, and studies using various cooling methods in this population report mean times to target temperature that range from 2.2 hours to over 16 hours (Diringer, 2004; Aujla et al., 2017).

Conclusions

This prospective interventional trial supports that ETM is a feasible TTM modality for severe TBI cases. As is expected in this patient population, there were challenges controlling temperature in individual cases, but overall, esophageal heat transfer demonstrated tight maintenance of goal temperature. The absence of established TTM guidelines makes device evaluation more difficult, as there is no clear benchmark for adequate performance. However, the esophageal heat transfer device used in this study demonstrated comparable or superior performance to other commercially available TTM modalities and the low adverse event rate may offer advantages over more invasive methods with reported higher complication rates.

Author Disclosure Statement

Original study funded by Advanced Cooling Therapy, Inc., now Attune Medical. E.K. is an equity holder of Attune Medical. M.N. is an employee of Attune Medical. All other authors have no related disclosures.

References

Abou El Fadl MH, O’Phelan KH. Management of Traumatic Brain Injury: an Update. Neurol Clin 2017;35:641–653.

Aujla GS, Nattanmai P, Premkumar K, Newey CR. Comparison of two surface cooling devices for temperature management in a neurocritical care unit. Ther Hypothermia Temp Manag 2017;7:147–151.

Badjatia N. Hypothermia and fever control in brain injury. Crit Care Med 2009;37(7 Suppl):S250–S257.

CDC Report to Congress: traumatic Brain Injury in the United States—Epidemiology and Rehabilitation. Atlanta, GA: U.S. Department of Health and Human Services—Centers for Disease Control and Prevention. 2015.

Clifton GL, Miller ER, Choi SC, Levin HS, McCauley S, Smith KR, Jr., Muizelaar JP, Wagner FC, Jr., Marion DW, Luerssen TG, Chesnut RM, Schwartz M. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 2001;344:556–563.

Clifton GL, Valadka A, Zygun D, Coffey CS, Drever P, Fourwinds S, Janis LS, Wilde E, Taylor P, Harshman K, Conley A, Puccio A, Levin HS, McCauley SR, Bucholz RD, Smith KR, Schmidt JD, Scott JN, Yonas H, Onkonwo DO. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: hypothermia II): A randomised trial. Lancet Neurol 2011;10:131–139.

Cooper DJ, Nichol AD, Bailey M, Bernard S, Cameron PA, Pili-Floury S, Forbes A, Gantner D, Higgins AM, Huet O, Kasza J, Murray L, Newby L, Presneill JJ, Rashford S, Rosenfeld JV, Stephenson M, Vallance S, Varma D, Webb SAR, Trapani T, McArthur C. Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury: the POLAR Randomized Clinical Trial. JAMA 2018;320:2211–2220.

Crossley S, Reid J, McMlatchie R, Hayton J, Clark C, MacDougall M, Andrews PJ. A systematic review of therapeutic hypothermia for adult patients following traumatic brain injury. Crit Care 2014;18:R75.
Diringer MN. Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system. Crit Care Med 2004;32:559–564.

Faul M, Coronado V. Epidemiology of traumatic brain injury. Handb Clin Neurol 2015;127:3–13.

Gierman JL, Shutez WP, Sr., Pearl GI, Foreman ML, Hohnmann SE, Shutez WP, Jr. Thermoregulatory catheter-associated inferior vena cava thrombus. Proc (Bayl Univ Med Cent) 2013;26:100–102.

Gillon S, Ammar T, Adlam M, Pahl C. Thermoregulatory central venous catheter-associated thrombus—echocardiographic detection and novel approach to management. J Intensive Care Soc 2015;16:71–74.

Goury A, Poirson F, Chaput U, Voicu S, Garcon P, Beeken T, Malissin I, Kerdjana L, Chelly J, Vodovar D, Haikel O, Ekerhian JM, Marteau P, Vicaut E, Megarbane B, Deyen. Targeted Temperature Management Using The “Esophageal Cooling Device” After Cardiac Arrest (The COOL Study): a feasibility and safety study. Resuscitation 2017;121:54–61.

Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC. Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke 2008;39:3029–3035.

Hegazy AF, Lapierre DM, Butler R, Althenayan E. Temperature control in critically ill patients with a novel esophageal cooling device: a case series. BMC Anesthesiol 2015;15:152.

Hegazy AF, Lapierre DM, Butler R, Martin J, Althenayan E. The esophageal cooling device: a new temperature control tool in the intensivist’s arsenal. Heart Lung 2017;46:143–148.

Khan I, Haymore J, Barnaba B, Armahizer M, Melinosky C, Bautista MA, Blaber B, Chang WT, Parikh G, Motta M, Badjatia N. Esophageal cooling device versus other temperature modulation devices for therapeutic normothermia in subarachnoid and intracranial hemorrhage. Ther Hypothermia Temp Manag 2018;8:53–58.

Kinoshita K. Traumatic brain injury: pathophysiology for neurocritical care. J Intensive Care 2016;4:29.

Lau E, Bajzer C, Menon V. Inferior vena cava thrombus associated with intravascular cooling catheter. Resuscitation 2010;81:1457–1458.

Marion DW, Penrod LE, Kelsey SF, Obrist WD, Kochanek PM, Palmer AM, Wisniewski SR, DeKosky ST. Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med 1997;336:540–546.

Marion DW, Regas LE. Revisiting therapeutic hypothermia for severe traumatic brain injury… again. Crit Care 2014;18:160.

Markota A, Fluher J, Kit B, Balazic P, Sinkovic A. The introduction of an esophageal heat transfer device into a therapeutic hypothermia protocol: a prospective evaluation. Am J Emerg Med 2016;34:741–745.

Markota A, Košir AS, Balazic P, Živko I, Sinković A. A novel esophageal heat transfer device for temperature management in an adult patient with severe meningitis. J Emerg Med 2017;52: e27–e28.

Maze R, Le May MR, Froeschl M, Hazra SK, Wells PS, Osborne C, Labinaz M, Hibbert B, So D. Endovascular cooling catheter related thrombosis in patients undergoing therapeutic hypothermia for out of hospital cardiac arrest. Resuscitation 2014;85:1354–1358.

Polderman KH. Induced hypothermia and fever control for prevention and treatment of neurological injuries. Lancet 2008;371:1955–1969.

Prunet B, Lacroix G, Bordes J, Poyet R, D’Aranda E, Goutorbe P. Catheter related venous thrombosis with cooling and warming catheters: two case reports. Cases J 2009;2:8857.

Puccio AM, Fischer MR, Jankowitz BT, Yonas H, Darby JM, Okonkwo DO. Induced normothermia attenuates intracranial hypertension and reduces fever burden after severe traumatic brain injury. Neurocrit Care 2009;11:82–87.

Reccius A, Mercado P, Vargas P, Canals C, Montes J. Inferior vena cava thrombosis related to hypothermia catheter: report of 20 consecutive cases. Neurocrit Care 2015;23:72–77.

Simosa HF, Petersen DJ, Agarwal SK, Burke PA, Hirsch EF. Increased risk of deep venous thrombosis with endovascular cooling in patients with traumatic head injury. Am Surg 2007;73:461–464.

Wang X, Moy BT, Henndlmayr BJ, Krainski F, Duvall WL, Fernandez AB. Intravascular Cooling Catheter-Related Venous Thromboembolism After Hypothermia: a Case Report and Review of the Literature. Ther Hypothermia Temp Manag 2018;8:117–120.

Williams D, Leslie G, Kyriazis D, O’Donovan B, Bowes J, Dingley J. Use of an esophageal heat exchanger to maintain core temperature during burn excisions and to attenuate pyrexia on the burns intensive care unit. Case Rep Anesthesiol 2016;2016:6.

Address correspondence to:

Faraaz Bhatti, MD, MRCEM
Department of Emergency Medicine
Bradford Teaching Hospitals NHS Foundation Trust
Bradford BD9 6RJ
United Kingdom

E-mail: faraaz.bhatti@nhs.net